Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-2: Tirzepatide in adults with type 2 diabetes and overweight/obesity
jRCT2031200440Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM), obesity and Overweight (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percent Change from Randomization in Body Weight and Percentage of Participants Who Achieve ≥5% Body Weight Reduction from Randomization. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on jRCT2031200440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200440.